指南与共识泌尿生殖技术与安全CTMRPET

晚期前列腺癌的最佳影像学策略:ASCO 指南

Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2020-01-15

ASCO 联合多学科专家组基于 2013 年至 2018 年 8 月的系统文献回顾(纳入 35 项研究)制定本指南,针对疑似高危、初诊未治转移、局部治疗后疑似复发及系统治疗中进展等不同晚期前列腺癌临床场景,推荐使用传统影像(CT、骨扫描和/或前列腺 MRI)和/或新一代影像(PET、PET/CT、PET/MRI 或全身 MRI)。

要点

  • 晚期前列腺癌应根据具体临床场景选用传统影像和/或新一代影像。
  • 传统影像定义为 CT、骨扫描和/或前列腺 MRI。
  • 新一代影像包括 PET、PET/CT、PET/MRI 或全身 MRI。

核心结论

  • 对于晚期前列腺癌患者,应根据临床场景使用一种或多种影像学检查:传统影像(定义为 CT、骨扫描和/或前列腺 MRI)和/或新一代影像(PET、PET/CT、PET/MRI 或全身 MRI)。

研究设计与样本

  • ASCO 联合腹部放射学会、美国放射学会、核医学与分子影像学会、美国泌尿外科学会、美国放射肿瘤学会和泌尿肿瘤学会组成专家组,对 2013 年至 2018 年 8 月的文献进行系统回顾。
  • 纳入标准为完全发表的英文系统综述(含或不含 Meta 分析)、比较至少 2 种影像模态的严格实施的 III 期随机对照试验报告,以及报告单一影像模态疗效的非比较性研究。
  • 共 35 项研究符合纳入标准并构成证据基础,包括 17 项系统综述(含或不含 Meta 分析)和 18 篇原始研究论文。
  • 指南呈现了代表不同前列腺癌疾病状态的索引病例,包括疑似高危疾病、初诊未治转移性疾病、局部治疗后疑似复发疾病以及接受系统治疗期间进展性疾病。

临床应用与阅片要点

  • 指南推荐,对于晚期前列腺癌患者,应根据临床场景使用一种或多种影像学检查:传统影像(定义为 CT、骨扫描和/或前列腺 MRI)和/或新一代影像(PET、PET/CT、PET/MRI 或全身 MRI)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups.

METHODS: An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality.

RESULTS: A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles.

RECOMMENDATIONS: One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020. PMID: 31940221. doi:10.1200/JCO.19.02757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。